Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
Sancho-Saldaña A, Gil-Sánchez A, González-Mingot C, Peralta S, Solana MJ, Torres P, Juanes A, Quibus L, Ruiz E, Sanpedro E, Quirant-Sánchez B, Martínez-Cáceres E, Ramo Tello C, Presas-Rodríguez S, García Rubio S, Baron BP, Ramió-Torrentà L, Sotoca J, González-Suárez I, Eichau S, Prieto-González JM, Blasco Quilez MR, Sabín-Muñoz J, Sánchez-López AJ, Llorens Calatayud G, Calles C, Sempere ÁP, Garcés M, Carmona O, Moral E, Hervás JV, Blanco Y, Sola-Valls N, Tellez Lara N, Forero L, Brieva L.
Sancho-Saldaña A, et al. Among authors: juanes a.
J Clin Med. 2023 Nov 23;12(23):7243. doi: 10.3390/jcm12237243.
J Clin Med. 2023.
PMID: 38068295
Free PMC article.